Notice2022-26888
Agency Forms Undergoing Paperwork Reduction Act Review
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 12, 2022
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 237 (Monday, December 12, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 237 (Monday, December 12, 2022)]
[Notices]
[Pages 76051-76052]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-26888]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-23-1279]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``WISEWOMAN National Program Evaluation'' to
the Office of Management and Budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on August 22, 2022 to obtain
comments from the public and affected agencies. CDC received two
comments related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to <a href="http://www.reginfo.gov/public/do/PRAMain">www.reginfo.gov/public/do/PRAMain</a>. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
WISEWOMAN National Program Evaluation (OMB Control No. 0920-1279,
Exp. 12/31/2022)--Extension--National Center for Chronic Disease
Prevention and Health Promotion (NCCDPHP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The CDC has supported the WISEWOMAN (Well-Integrated Screening and
Evaluation for Women Across the Nation) program since 1995. The
WISEWOMAN program is designed to serve low-income women ages 40-64 who
have elevated risk factors for cardiovascular disease (CVD) and have no
health insurance, or are underinsured for medical and preventive care
services. Through the WISEWOMAN program, women have access to screening
services for selected CVD risk factors such as elevated blood
cholesterol, hypertension, and abnormal blood glucose levels; referrals
to heathy behavior support programs; and referrals to medical care.
WISEWOMAN participants must be co-enrolled in the CDC-sponsored
National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
The WISEWOMAN program is administered through cooperative
agreements with state, territorial, or tribal health departments. Each
WISEWOMAN recipient submits to CDC an annual progress report that
describes program objectives and activities, and semi-annual data
reports (known as minimum data elements, or MDEs) on the screening,
assessment, and healthy behavior support services offered to women who
participate in the program. Participant-level MDEs are de-identified
prior to transmission to CDC.
In 2018, CDC released the fifth funding opportunity announcement
(FOA) for the WISEWOMAN program (DP18-1816), which resulted in five-
year cooperative agreements with 24 state, territorial, and tribal
health departments, including six new and 18 continuing awardees from
the previous NOFO. Key program elements were retained (e.g., provision
of screening services, promotion of healthy lifestyle behaviors, and
linkage to healthy behavior support services and community based
resources), but a number of changes were incorporated into the program
at that time. The current FOA reflects increased emphasis on three
strategies to reduce CVD risk and support hypertension control and
management, including: (1) tracking and monitoring clinical measures;
(2) implementing team-based care; and (3) linking community resources
and clinical services to support care coordination, self-management,
and lifestyle change.
CDC seeks to conduct a multi-component evaluation to assess the
effectiveness of the program on individual, organizational, and
community-level outcomes. The in-depth assessment is designed to
complement the routine progress and MDE information already being
collected from WISEWOMAN program recipients. The data collection
focuses on obtaining qualitative and quantitative information at the
organizational and community levels about process and procedures
implemented, and barriers, facilitators, and other contextual factors
that affect program implementation and participant outcomes. Data
collection activities include a Program Survey with all WISEWOMAN
awardee programs, administered in the second and fourth program years,
and a one-time site visit to each recipient spread across the three-
year data collection effort. During site visits, semi-structured
interviews will be conducted with WISEWOMAN staff members and staff at
partner organizations, such as clinical providers and community-based
resource providers, who are positioned to provide a variety of
perspectives on program implementation.
CDC requests OMB approval for a one-year extension of this data
collection, and requests approval for an estimated 84 annual burden
hours. Participation is voluntary and there are no costs to respondents
other than their time.
Estimated Annualized Burden Hours
[[Page 76052]]
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
WISEWOMAN Recipient Administrators.... Program survey.......... 16 1 1
Site Visit Discussion 8 1 90/60
Guide.
Innovation Site Visit 2 1 45/60
Discussion Guide.
Recipient partners.................... Site Visit Discussion 16 1 1
Guide.
Innovation Site Visit 2 1 45/60
Discussion Guide.
Healthy behavior support staff........ Site Visit Discussion 16 1 1
Guide.
Innovation Site Visit 2 1 45/60
Discussion Guide.
Clinical providers.................... Site Visit Discussion 16 1 1
Guide.
Innovation Site Visit 2 1 45/60
Discussion Guide.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2022-26888 Filed 12-9-22; 8:45 am]
BILLING CODE 4163-18-P
</pre></body>
</html>Indexed from Federal Register on December 12, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.